Clinical Trial Update: Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of mosunetuzumab and polatuzumab vedotin as frontline therapy for untreated follicular lymphoma; the study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Mosunetuzumab (mosunetuzumab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Lymphoma, Follicular, Follicular Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING